Compare Simon Property Group Inc (SPG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Simon Property Group Inc trades at $219.28 (market cap $71.03B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Simon Property Group Inc pays a 4.05% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Simon Property Group Inc nearer its low. Which is the better fit depends on your goals.
| SPG | XBI | |
|---|---|---|
Market Cap | $71.03B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $236.70 | $164.28 |
52-Week Low | $169.22 | $86.92 |
Enterprise Value | $99.48B | — |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Simon Property Group (SPG) trades at $220.31, down 0.11% on the day, with a bearish technical signal as price tests support near $218. The company reported strong Q2 2026 FFO of $3.29 per share, beating estimates, and raised full-year guidance, driven by robust leasing and retailer sales growth. Financials show high profitability with a net income margin of 66.57% and ROE of 135.7%, though valuation ratios like P/S of 10.29 and P/B of 16.16 appear elevated.
Outlook remains positive with analyst consensus favoring a Buy rating and a $226.58 price target, supported by operational strength and dividend reliability. Key risks include high leverage with $24.21B in long-term debt and sensitivity to interest rates. Earnings growth and strategic acquisitions present upside, but macroeconomic headwinds could pressure retail real estate demand.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
